Godrej Properties enters into JV with Royale Builders
Godrej Properties has entered into a joint venture with Royale Builders and Developers to develop a 13-acre land parcel on Bellary Road in North Bangalore. It plans to develop 1.34 million sq ft residential project on the plot.It is the company’s fifteenth project in Bengaluru.On Thursday, it announced a development management contract with Manyata Developers of Bengaluru to develop a residential project in Bengaluru.On 14 September, it forged a JV with Mumbai based real estate company Nirmal Ventures to develop a 2.1 million sq. ft residential project on 14 acres in Thane near Mumbai.
Cadila gets USFDA approval for doxycycline
Cadila gets USFDA approval for doxycycline tablets USP in strengths of 50mg, 75mg, 100 mg and 150 mg (used to treat many different bacterial infections). The product shall be manufactured at Ahmedabad SEZ – Positive for Cadila; Stock is up 1%+.
HCC lavasa lenders invoke debt restructuring
Hindustan Construction Company (HCC) rose over 7% touching to Rs35.15, after the company said that lenders had decided to invoke the strategic debt restructuring scheme for its Lavasa township project.
Hindustan Construction Company (HCC) said Lavasa lenders will invoke strategic debt restructuring ( SDR). The SDR process will involve lowering of debt burden by converting a part of lenders loans into equity, along with the implementation of the proposed business plan and infusion of fresh capital by a financial or strategic investor to implement the project and help protect the value of the asset within the timelines prescribed by RBI in its notification
BHEL’s outlook revised by India Ratings & Research
India Ratings & Research (Ind-Ra) has revised BHEL’s outlook to stable from negative while affirmed the rating for bank facilities ( fund based as well as non- fund based) at IND AA+ indicating stable outlook; positive.
Zydus Cadila gets final nod for doxycycline tablets
Drug firm Zydus Cadila has received final approval from the US health regulator to market doxycycline tablets, used for treatment of different types of bacterial infections such as acne and eye infection.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 50 mg, 75 mg, 100 mg and 150 mg.The company will manufacture the drug at the group's formulations facility at the pharma SEZ in Ahmedabad.It has more than 155 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
Visit Here- http://www.capitalstars.com/
0 Comments